Keys to cannabinoid success

Cannabinoids are thought to be useful in CNS disorders because they modulate neurotransmission and calcium homeostasis, as well as having anti-inflammatory and antioxidant actions. But as with other applications of the class, the problem has been avoiding psychotropic side effects.

KeyNeurotek AG thinks it can avoid these difficulties via a dual strategy. First, the cannabinoid receptor agonist it in-licensed from Bayer AG (FSE:BAYG; BAY, Leverkusen, Germany) is structurally unrelated to other known cannabinoid receptor agonists and appears to produce fewer side effects for as yet unknown reasons. Second, the company is targeting traumatic brain injury (TBI), an acute indication where side effects would be more acceptable. ...